Executive Summary
The S&P 500 Healthcare sector is exhibiting a clear bifurcation in Q2 2026: top-tier innovators like Vertex and Amgen are delivering double-digit revenue growth (12.5% and 10% YoY, respectively) and expanding margins, while legacy pharma giants like Pfizer and Merck face earnings headwinds from large acquisition-related charges and asset impairments.
A wave of aggressive M&A, particularly in biotech (Gilead's $11.2B in acquired IPR&D, Merck's Terns acquisition), is driving significant GAAP losses and depleting cash reserves, signaling a high-stakes bet on pipeline replenishment. Capital allocation patterns are diverging sharply, with Vertex and IDEXX aggressively buying back shares (combined ~$1.5B in H1 2026), while Amgen and Pfizer pause repurchases to fund deals. Insider activity is mixed but notable: Gilead's CEO sold ~$1.96M under a 10b5-1 plan, while Medtronic's top brass received substantial equity awards, suggesting confidence in long-term strategy. The most critical development is the sector-wide margin pressure from rising SG&A (Vertex +37% YoY) and R&D investment, even as top-line growth remains resilient.
Materiality, sentiment, and priority are scored by Gunpowder’s analysis pipeline. How we score filings →
Filing types in this digest: 10-Q · 8-K · Form 4
Tracking the trend? Catch up on the prior S&P 500 Healthcare Sector SEC Filings digest from August 03, 2026.
Investment Signals (11)
- Vertex Pharmaceuticals ↓ (BULLISH)▲
Revenue grew 12.5% YoY to $3.33B, net income up 6.5%, and aggressive buybacks ($802M in H1) reduced share count 1.4% YoY, boosting EPS. However, SG&A surged 37% YoY, a red flag for cost control.
- Amgen ↓ (MIXED)▲
Total revenues up 10% YoY to $10.1B, GAAP EPS surged 65% to $4.37, and operating margin expanded 6.5pp to 36.8%. However, key products Prolia (-32%) and Otezla (-21%) are declining, and no share repurchases occurred in Q2.
- Gilead Sciences ↓ (BEARISH)▲
Revenue up 10% YoY to $7.8B, driven by HIV (+12%) and Trodelvy (+26%), but GAAP loss per share of $(8.45) due to $11.2B in acquired IPR&D. Cash reserves collapsed from $10.6B to $3.2B, signaling aggressive M&A risk.
- Pfizer ↓ (MIXED)▲
Revenue up 2.6% YoY to $15B, but swung to a net loss of $248M due to $4.3B in impairments. Raised full-year revenue guidance by $500M but reaffirmed EPS, absorbing a $0.10 hit from the Innovent deal.
- Merck & Co. ↓ (MIXED)▲
Sales up 5% YoY to $16.6B, with KEYTRUDA growing 5% and WINREVAIR surging 75%. However, GAAP loss per share of $(0.54) due to Terns acquisition charge, and legacy products like JANUVIA (-31%) are declining.
- IDEXX Laboratories ↓ (BULLISH)▲
Revenue up 9.7% YoY to $1.22B, net income up 15.1%, and CAG Diagnostics recurring revenue grew 11%. However, capital instrument revenue declined 19.5% and rapid assay growth was only 1%.
- Edwards Lifesciences ↓ (MIXED)▲
Net sales up 13.6% YoY to $1.74B, operating income up 24.8%, but net income fell 27.4% due to a $163.6M impairment and higher tax provision. Diluted EPS declined 26.3% to $0.42.
- Gilead CEO Insider Selling (BEARISH)▲
Chairman & CEO O'Day sold $1.96M in stock under a 10b5-1 plan at ~$130/share, a notable insider sale following the massive M&A spending.
- Medtronic Executive Equity Awards (BULLISH)▲
Chairman & CEO Martha Geoffrey received 41,533 ordinary shares and 103,831 PSUs, signaling strong alignment with long-term performance. CFO Pieton received 11,537 shares and 81,945 options.
- Baxter Tender Offer (NEUTRAL)▲
Commenced $500M tender offer for senior notes (2032-2051 maturities), a debt management move that reduces future interest expense but signals limited growth capex.
- J&J Leadership Transition (NEUTRAL)▲
Retirement of Innovative Medicine Chairman after 21-year tenure (business grew to $60B+), with smooth succession plan. No financial impact, but signals a strategic shift in leadership.
Risk Flags (10)
- Pfizer/Earnings Quality↓ [HIGH RISK]▼
Net loss of $248M in Q2 vs $2.9B profit a year ago, driven by $4.3B in non-cash impairments. Total assets declined $7B from Dec 2025, and equity fell to $85.5B.
- Gilead/Cash Burn↓ [HIGH RISK]▼
Cash and marketable securities dropped from $10.6B (Dec 2025) to $3.2B (June 2026), a 70% decline, due to $11.2B in acquisition-related outflows. This limits financial flexibility.
- Merck/GAAP Loss↓ [MEDIUM RISK]▼
GAAP loss per share of $(0.54) due to Terns acquisition charge, with GAAP gross margin declining 400 bps to 73.5%. Effective tax rate was (95.9)% due to non-deductible charges.
- Vertex/Cost Growth↓ [MEDIUM RISK]▼
SG&A expenses surged 37.1% YoY in Q2, significantly outpacing 12.5% revenue growth. If this trend continues, operating margins will compress.
- Amgen/Product Decline↓ [MEDIUM RISK]▼
Key products Prolia (-32% YoY), XGEVA (-34%), and Otezla (-21%) are declining sharply, offsetting growth from Repatha (+37%) and EVENITY (+38%). Portfolio concentration risk is rising.
- Edwards Lifesciences/Net Income Decline↓ [MEDIUM RISK]▼
Net income fell 27.4% in Q2 and 9.9% in H1, despite 13.6% revenue growth. The $163.6M impairment and higher tax provision ($356.7M vs $134.6M) are concerning.
- Baxter/CFO Resignation↓ [LOW RISK]▼
Interim CFO Anita Zielinski resigns effective Sept 15, 2026, with no successor announced. This creates leadership uncertainty during a debt restructuring phase.
- Gilead/Cell Therapy Decline↓ [MEDIUM RISK]▼
Cell Therapy sales declined 14% YoY, a key growth area that is underperforming. Veklury sales plunged 81%, removing a significant revenue contributor.
- IDEXX/Capital Revenue Decline↓ [LOW RISK]▼
CAG Diagnostics capital instrument revenue declined 19.5% YoY, indicating a potential slowdown in veterinary practice investment.
- Pfizer/COVID Revenue Volatility↓ [MEDIUM RISK]▼
Full-year guidance raised $500M but includes a $1B reduction in COVID product expectations, offset by $1.5B in non-COVID growth. COVID revenue remains unpredictable.
Opportunities (10)
- Vertex/CF Cystic Fibrosis Dominance↓ (OPPORTUNITY)◆
With 12.5% revenue growth and $2.1B in H1 net income, Vertex continues to dominate CF. The aggressive buyback ($802M in H1) at a reduced share count creates a powerful EPS tailwind.
- Merck/WINREVAIR Growth↓ (OPPORTUNITY)◆
WINREVAIR sales surged 75% YoY to $588M, a potential blockbuster in pulmonary hypertension. If this trajectory continues, it could offset legacy product declines.
- Amgen/Repatha & EVENITY Momentum↓ (OPPORTUNITY)◆
Repatha grew 37% and EVENITY grew 38% YoY, showing strong commercial execution. Non-GAAP operating income rose to $4.6B, providing cash for pipeline investment.
- Gilead/HIV & Trodelvy Strength↓ (OPPORTUNITY)◆
HIV portfolio grew 12% and Trodelvy grew 26% YoY, demonstrating core business resilience. The $11.2B in acquired IPR&D could yield future blockbusters if pipeline candidates succeed.
- IDEXX/Recurring Revenue Growth↓ (OPPORTUNITY)◆
CAG Diagnostics recurring revenue grew 11% reported and 10% organic, with inVue Dx installed base surpassing 9,000 instruments. This creates a sticky, high-margin revenue stream.
- Edwards Lifesciences/Operating Leverage↓ (OPPORTUNITY)◆
Operating income grew 24.8% YoY despite net income decline, and gross margin held at 77.5%. If the impairment and tax headwinds normalize, EPS could rebound sharply.
- Medtronic/Executive Alignment↓ (OPPORTUNITY)◆
Massive equity awards to top executives (CEO: 41,533 shares + 103,831 PSUs) signal strong confidence in long-term strategy. The stock at $85.39 may offer a favorable entry point.
- Pfizer/Cost Cutting Program↓ (OPPORTUNITY)◆
Announced additional $2.5B in productivity savings from 2027-2029, which could boost margins. The raised revenue guidance ($61.5B) suggests non-COVID products are gaining traction.
- Baxter/Debt Reduction↓ (OPPORTUNITY)◆
The $500M tender offer for high-coupon notes (2.539%-4.500%) will reduce interest expense and improve credit metrics, potentially leading to a credit rating upgrade.
- Danaher/Director Phantom Shares↓ (OPPORTUNITY)◆
Multiple directors were awarded phantom shares at $194.98, a price that may represent a floor. Director alignment through deferred compensation is a positive governance signal.
Sector Themes (6)
- M&A-Driven Earnings Volatility◆
3 of 6 major pharma/biotech companies (Pfizer, Merck, Gilead) reported GAAP losses due to acquisition-related charges totaling over $15B. This is a sector-wide theme of prioritizing pipeline over near-term earnings, creating valuation disconnects for value investors.
- Revenue Growth vs. Margin Compression◆
While 5 of 6 reporting companies showed YoY revenue growth (avg +9%), operating expenses grew faster at Vertex (+37% SG&A) and Pfizer (+15% OpEx). This suggests sector-wide margin pressure from R&D investment and SG&A inflation.
- Divergent Capital Allocation◆
Vertex and IDEXX are aggressively buying back shares (combined ~$1.5B in H1 2026), while Amgen paused repurchases and Gilead spent heavily on M&A. This creates a clear split between 'return to shareholders' and 'invest for growth' strategies.
- Legacy Product Decline vs. New Launch Momentum◆
Across the sector, legacy products are declining (Prolia -32%, JANUVIA -31%, Veklury -81%, Otezla -21%), while new launches like WINREVAIR (+75%), Repatha (+37%), and Trodelvy (+26%) are driving growth. Portfolio rotation is accelerating.
- Insider Activity Signals Confidence◆
Despite mixed earnings, insider activity is predominantly neutral-to-positive. Medtronic's top executives received large equity awards, and Danaher directors accepted phantom shares. The only notable sell was Gilead's CEO, which is under a 10b5-1 plan.
- Cash Conservation vs. Investment◆
Gilead's cash burn (70% decline in 6 months) contrasts with Pfizer's stable debt levels and Baxter's debt reduction. This indicates a sector-wide tension between investing in growth and maintaining balance sheet strength.
Watch List (8)
-
Watch Q3 2026 for SG&A growth trajectory. If SG&A continues to outpace revenue, margins could compress. Next earnings call expected late October 2026.
-
Monitor cash burn rate and pipeline updates from Arcellx, Tubulis, and Ouro Medicines acquisitions. Any clinical setbacks could further pressure the stock. Next earnings call expected late October 2026.
- 👁
Watch for further guidance adjustments on COVID products and the impact of the Innovent Biologics transaction. The $2.5B productivity savings plan (2027-2029) needs detailed execution timeline.
-
Monitor WINREVAIR sales trajectory and KEYTRUDA patent cliff preparations. The Terns acquisition integration and pipeline updates are key catalysts. Next earnings call expected late October 2026.
-
Interim CFO resignation effective Sept 15, 2026. Watch for successor announcement and the outcome of the $500M tender offer. Any delay in CFO appointment could be a negative signal.
-
Watch for normalization of tax provision and impairment charges. If Q3 2026 shows EPS recovery, the stock could re-rate. Next earnings call expected late October 2026.
-
Monitor execution against the large equity awards granted to executives. The stock at $85.39 is near 52-week lows; any positive guidance or product news could trigger a rally.
-
Watch for recovery in capital instrument revenue and rapid assay growth. The inVue Dx installed base (9,000+) is a key metric for future consumable revenue. Next earnings call expected late October 2026.
Filing Analyses
(36)
04-08-2026
Vertex Pharmaceuticals reported strong financial results for Q2 and H1 2026, with total revenues increasing 12.5% YoY to $3,333.9M in Q2 and 10.2% to $6,320.8M in H1, driven entirely by product revenue growth. Net income rose 6.5% YoY to $1,099.8M in Q2 and 26.9% to $2,131.2M in H1. However, operating expenses grew faster than revenue in Q2 (15.1% vs 12.5%), and the company continued aggressive share repurchases ($457.7M in Q2, $802.2M in H1), reducing diluted share count by 1.4% YoY.
- · Other revenues dropped to $0 in both Q2 and H1 2026 from $20.7M and $30.7M respectively in the prior year periods.
- · SG&A expenses surged 37.1% YoY in Q2 2026 to $582.2M, significantly outpacing revenue growth.
- · R&D expenses remained nearly flat in H1 2026 at $1,955.4M vs $1,958.1M in H1 2025.
- · The company had no intangible asset impairment charge in H1 2026 vs a $379.0M charge in H1 2025.
- · Cash provided by operating activities increased 35.0% to $2,553.5M in H1 2026.
- · Vertex repurchased 1.8M shares for $802.2M in H1 2026, reducing outstanding shares by 0.3% since year-end 2025.
- · Total assets grew to $27,423.3M as of June 30, 2026, up 6.9% from $25,643.0M at December 31, 2025.
- · Accumulated other comprehensive income swung from a loss of $15.9M to a gain of $48.5M, primarily due to foreign currency forward contracts.
04-08-2026
Pfizer's Q2 2026 (three months ended June 28, 2026) total revenues rose 2.6% YoY to $15,034M, driven by growth in alliance revenues (+18.7%) and royalty revenues (+11.3%), which partially offset a slight decline in product revenues (-0.8%). However, the company reported a net loss attributable to common shareholders of $248M in Q2 2026 versus a net income of $2,910M in Q2 2025, swinging to a loss largely due to a $3,716M charge in other deductions partly reflecting asset write-offs and impairments ($4,425M in H1 2026 vs $498M in H1 2025). For the six months ended June 28, 2026, net income fell 58.5% to $2,440M from $5,877M in the prior year period.
- · Total assets decreased to $201,131M as of June 28, 2026, from $208,160M at December 31, 2025.
- · Total equity declined to $85,492M from $86,775M over the same period.
- · Long-term debt stood at $60,495M, slightly down from $61,641M at year-end 2025.
- · Cash and cash equivalents fell to $976M from $1,142M at December 31, 2025.
- · The company reported a net gain of $1,870M from the sale of its investment in ViiV during H1 2026.
- · Share repurchases were negligible; treasury stock remained nearly flat at 3,942 million shares.
- · Dividends declared were $0.86 per share in both Q2 2026 and Q2 2025.
04-08-2026
IDEXX Laboratories reported strong Q2 2026 results with revenue of $1,217M (+10% reported, +9% organic) and EPS of $4.27 (+18% reported, +15% comparable), driven by double-digit CAG Diagnostics recurring revenue growth of 11% reported and 10% organic. However, CAG Diagnostics capital instrument revenues declined 19% reported and 20% organic due to lapping the broad availability of IDEXX inVue Dx in Q2 2025, and rapid assay product revenues grew only 1%. The company narrowed its 2026 revenue guidance to $4,700M-$4,745M (up $5M at midpoint) and raised EPS outlook to $14.69-$14.94, while facing a $15M headwind from a stronger U.S. dollar.
- · IDEXX inVue Dx installed base surpassed 9,000 instruments with over 1,600 placements in Q2 2026.
- · CAG Diagnostics capital instrument revenues declined 19% reported and 20% organic due to lapping Q2 2025 broad availability of IDEXX inVue Dx.
- · Rapid assay product revenues grew only 1% as reported and organic, impacted by volume shifts from adoption of Catalyst Pancreatic Lipase Test.
- · International CAG Diagnostics recurring revenue grew 14% reported and 12% organic, outpacing U.S. growth of 10% reported and organic.
- · 2026 EPS outlook raised to $14.69-$14.94 from $14.45-$14.90, with $0.14 benefit from operational performance and $0.05 from higher share-based compensation, offset by $0.05 FX headwind.
- · 2026 operating margin outlook raised to 32.3%-32.5% from 32.1%-32.5%, with expansion of 70-90 bps.
- · 2026 free cash flow forecast raised to 90%-100% of net income from 85%-95%.
- · 2026 share-based compensation tax benefit forecast increased to ~$19M from ~$15M.
- · 2026 effective tax rate forecast lowered to ~21.1% from ~21.4%.
- · 2026 Investor Day scheduled for August 13, 2026.
- · Foreign currency exchange rate assumptions: euro $1.14, British pound $1.32, Canadian dollar $0.70, Australian dollar $0.69, Japanese yen ¥162, Chinese renminbi ¥6.80, Brazilian real R$5.20.
04-08-2026
Merck reported Q2 2026 total worldwide sales of $16.6B, up 5% YoY, driven by oncology strength and new launches. However, the company posted a GAAP loss per share of $0.54 and a non-GAAP loss per share of $0.13, both impacted by a $2.31 per share charge for the acquisition of Terns Pharmaceuticals. While KEYTRUDA/KEYTRUDA QLEX sales grew 5% to $8.4B and WINREVAIR surged 75% to $588M, several legacy products declined, including JANUVIA/JANUMET (-31%), VAXNEUVANCE (-35%), and LAGEVRIO (-95%).
- · GAAP gross margin decreased to 73.5% from 77.5% due to higher amortization of intangible assets and inventory write-downs.
- · Non-GAAP gross margin decreased to 81.1% from 82.2% due to higher inventory write-downs.
- · GAAP effective income tax rate was (95.9)% due to a 108.9 percentage point unfavorable impact from the Terns acquisition charge with no tax benefit.
- · Non-GAAP effective income tax rate was 160.3% due to a 146.2 percentage point unfavorable impact from the Terns acquisition charge with no tax benefit.
- · Full-year 2026 Non-GAAP EPS guidance is $2.66 to $2.76, including $2.43 per share in charges for the Terns acquisition.
- · OHTUVAYRE sales of $204 million in Q2 2026, obtained via the October 2025 acquisition of Verona Pharma plc.
- · PROQUAD, M-M-R II and VARIVAX sales declined 3% YoY due to lower U.S. demand.
- · Lynparza sales were relatively flat at -1% YoY.
- · BRAVECTO line of products sales grew 7% to $359 million.
04-08-2026
Pfizer reported Q2 2026 revenues of $15.0 billion, up 1% operationally year-over-year, with launched and acquired products growing 18% operationally. However, reported net loss was $(248) million due to $4.3 billion in non-cash intangible asset impairments, and adjusted diluted EPS was flat at $0.77. The company raised its full-year 2026 revenue guidance midpoint by $500 million to $61.5 billion, but reaffirmed adjusted EPS guidance of $2.80-$3.00, absorbing a $0.10 impact from the Innovent Biologics transaction.
- · Pfizer raised full-year 2026 revenue guidance by $500M at the midpoint to $61.5B, reflecting better non-COVID product performance (+$1.5B) offset by lower COVID product expectations (-$1.0B).
- · Full-year 2026 adjusted diluted EPS guidance reaffirmed at $2.80-$3.00, absorbing a $0.10 impact from the Innovent Biologics transaction.
- · Pfizer announced additional anticipated productivity enhancement savings of $2.5B to be realized from 2027 through 2029.
- · No share repurchases have been completed in 2026; remaining authorization is $3.3B but guidance does not anticipate any repurchases in 2026.
- · Pfizer completed the Innovent Biologics licensing agreement on July 10, 2026, with a $650M acquired in-process R&D charge to be recorded in Q3 2026.
- · Braftovi Phase 3 BREAKWATER trial showed a 56% reduction in risk of disease progression or death in mCRC with BRAF V600E mutation.
- · Hympavzi received FDA expanded approval for hemophilia A or B with inhibitors and pediatric patients aged 6-11 years.
- · Comirnaty received EC marketing authorization for 2026-2027 formula targeting XFG variant.
04-08-2026
Baxter International Inc. announced on August 4, 2026, the commencement of cash tender offers to purchase up to $500 million in aggregate purchase price (excluding accrued and unpaid interest) of four series of its outstanding senior notes. The offers target notes with maturities ranging from 2032 to 2051 and coupon rates between 2.539% and 4.500%. The company is using an offer to purchase document dated August 4, 2026, and the offers are not being made in jurisdictions where non-compliant with local laws.
- · The tender offers are being made pursuant to an offer to purchase dated August 4, 2026.
- · The offers are not being made to holders in any jurisdiction where compliance with securities or blue sky laws would be violated.
- · The press release announcing the offers is attached as Exhibit 99.1 to the 8-K filing.
04-08-2026
Johnson & Johnson announced the retirement of Jennifer Taubert, Executive Vice President and Worldwide Chairman of Innovative Medicine, after a 21-year tenure during which the business grew to over $60 billion in annual revenue. She will be succeeded by Tom Cavanaugh, currently Company Group Chairman for North America, effective September 1, 2026. The transition is described as smooth and planned, with no negative financial impact indicated.
- · Jennifer Taubert's retirement follows a 21-year tenure at Johnson & Johnson.
- · Tom Cavanaugh joined Johnson & Johnson in 2017 and previously spent nearly 15 years at Celgene.
- · Tom Cavanaugh will join the Johnson & Johnson Executive Committee effective September 1, 2026.
- · Jennifer Taubert was recognized for 10 consecutive years among Fortune’s Most Powerful Women.
04-08-2026
Director Crawford Frederick John was awarded 544 Humana Common. Crawford Frederick John holds 544 shares after the transaction.
- · Director Crawford Frederick John was awarded 544 Humana Common
04-08-2026
Amgen reported total revenues of $10.1B in Q2 2026, up 10% year-over-year, driven by product sales growth of 9% to $9.537B. GAAP EPS surged 65% to $4.37, while non-GAAP EPS increased only 4% to $6.29. However, several key products declined sharply, including Prolia (-32%), XGEVA (-34%), Otezla (-21%), and KYPROLIS (-17%), partially offsetting strong growth from Repatha (+37%), EVENITY (+38%), and UPLIZNA (+90%).
- · No share repurchases occurred in Q2 2026; full-year 2026 repurchase cap is $3.0B.
- · GAAP operating income increased from $2.7B to $3.5B YoY, with operating margin up 6.5 percentage points to 36.8%.
- · Non-GAAP operating income increased from $4.3B to $4.6B, but operating margin fell 0.5 percentage points to 48.4%.
- · GAAP tax rate rose 5.5 percentage points to 14.2%; non-GAAP tax rate rose 1.4 percentage points to 15.6%.
- · Total debt increased $2.7B from year-end 2025 to $57.3B as of June 30, 2026.
- · MariTide has six ongoing Phase 3 studies (MARITIME-1, -2, -CV, -HF, -OSA-1, -OSA-2) plus a switch study and two extension studies; three additional T2D Phase 3 studies planned in 2026.
- · AMG 513 development discontinued, though Phase 1 study remains ongoing to follow enrolled participants.
- · Repatha VESALIUS-CV subanalysis on PCI patients presented at EuroPCR 2026.
04-08-2026
Gilead Sciences reported Q2 2026 total revenues of $7.8B, up 10% YoY, driven by strong HIV portfolio (+12%), Trodelvy (+26%), and Livdelzi. However, the company posted a GAAP diluted loss per share of $(8.45) versus a profit of $1.56 in Q2 2025, primarily due to $11.2B in acquired IPR&D expenses from the acquisitions of Arcellx, Tubulis, and Ouro Medicines. Cell Therapy sales declined 14% YoY and Veklury sales plunged 81%, while cash and marketable securities dropped from $10.6B at year-end 2025 to $3.2B as of June 30, 2026, reflecting significant acquisition-related outflows.
- · Product gross margin remained relatively flat at 79.3% in Q2 2026 vs 78.7% in Q2 2025.
- · Non-GAAP product gross margin also remained flat at 86.9% in Q2 2026 vs Q2 2025.
- · R&D expenses were $1.8B in Q2 2026 vs $1.5B in Q2 2025; non-GAAP R&D expenses were $1.4B vs $1.5B.
- · SG&A expenses were $1.9B in Q2 2026 vs $1.4B in Q2 2025; non-GAAP SG&A expenses were $1.5B vs $1.4B.
- · GAAP effective tax rate was (2.4)% in Q2 2026 vs 19.3% in Q2 2025.
- · Non-GAAP effective tax rate was (11.4)% in Q2 2026 vs 18.8% in Q2 2025.
- · Full year 2026 product sales guidance raised to $30.1B - $30.4B (from $30.0B - $30.4B).
- · Full year 2026 product sales excluding Veklury guidance raised to $29.8B - $30.1B (from $29.4B - $29.8B).
- · Full year 2026 Veklury sales guidance lowered to ~$300M (from ~$600M).
- · Full year 2026 GAAP diluted loss per share guidance worsened to $(3.75) - $(3.40) from $(3.25) - $(2.85).
- · Full year 2026 non-GAAP diluted loss per share guidance improved to $(0.65) - $(0.30) from $(1.05) - $(0.65).
- · FDA accepted supplemental NDA for Yeztugo (lenacapavir) once-weekly oral PrEP with PDUFA date Feb 2, 2027.
- · Positive Phase 3 results for islatravir/lenacapavir once-weekly oral regimen in HIV (ISLEND-1 and ISLEND-2).
- · FDA accelerated approval for Hepcludex for chronic HDV infection.
- · FDA approval of Trodelvy for 1L mTNBC as single agent or with Keytruda.
- · Discontinuation of Phase 3 EVOKE-03 study (Trodelvy + Keytruda in 1L NSCLC).
- · Completed acquisition of Tubulis for $3.15B upfront; Ouro Medicines for $1.675B upfront (shared with Lakefront).
- · Board declared Q3 2026 dividend of $0.82 per share, payable Sept 29, 2026.
- · Year-to-date cash outflows of $11.3B related to acquisitions, $2.8B debt repayments, $2.1B dividends, $774M stock repurchases.
- · Year-to-date cash inflows of $4.1B net proceeds from debt financing and $6.1B operating cash flow.
04-08-2026
EVP, General Counsel Gallman Cari had withheld for taxes 543 Common Stock, $0.10 par value at $65.31 (~$35.5K). Gallman Cari holds 13,649 shares after the transaction.
- · EVP, General Counsel Gallman Cari exercised/converted 1,061 Common Stock, $0.10 par value
- · EVP, General Counsel Gallman Cari had withheld for taxes 543 Common Stock, $0.10 par value at $65.31 (~$35.5K)
- · EVP, General Counsel Gallman Cari exercised/converted 1,061 Restricted Stock Units
04-08-2026
IDEXX Laboratories reported strong Q2 2026 results with total revenue of $1,216.6M for the three months ended June 30, 2026, up 9.7% from $1,109.5M in Q2 2025. Net income rose 15.1% to $338.4M from $294.0M, driven by robust growth in the Companion Animal Group (CAG) segment, particularly IDEXX VetLab consumables (+14.7%) and reference laboratory services (+10.6%). However, CAG Diagnostics capital instrument revenue declined 19.5% to $47.2M, and the company continued significant share repurchases ($698M in the first half of 2026), while total debt increased to $968.9M from $847.8M at year-end 2025.
- · Diluted EPS for Q2 2026 was $4.27, up from $3.63 in Q2 2025.
- · Basic EPS for Q2 2026 was $4.29, up from $3.66 in Q2 2025.
- · Total stockholders' equity increased slightly to $1,612.6M as of June 30, 2026 from $1,605.4M at December 31, 2025.
- · Accumulated other comprehensive loss improved to $(63.5M) from $(68.8M).
- · Water segment revenue grew 14.8% to $58.6M in Q2 2026 from $51.0M in Q2 2025.
- · LPD segment revenue grew 10.8% to $35.2M in Q2 2026 from $31.8M in Q2 2025.
- · Total debt (Credit Facility + current portion of long-term debt + long-term debt) was $968.9M as of June 30, 2026, up from $847.8M at December 31, 2025.
- · Share-based compensation expense was $32.4M for H1 2026 vs $29.5M for H1 2025.
- · Depreciation and amortization was $78.7M for H1 2026 vs $69.8M for H1 2025.
- · The company recorded a $5.0M impairment charge in H1 2026.
- · Proceeds from exercises of stock options and employee stock purchase plans were $51.1M in H1 2026 vs $24.5M in H1 2025.
04-08-2026
Edwards Lifesciences reported Q2 2026 net sales of $1,741.0M, up 13.6% YoY from $1,532.2M, and net income attributable to the company of $241.9M, down 27.4% from $333.2M in Q2 2025. For the six-month period, net sales grew 15.1% to $3,389.6M, but net income fell 9.9% to $622.6M, pressured by a $163.6M impairment loss and a significantly higher tax provision ($356.7M vs $134.6M). The company also increased share repurchases and recorded a noncontrolling interest of $106.9M, reflecting recent business combinations.
- · Gross profit margin improved to 77.5% in Q2 2026 (77.5% in Q2 2025) and 77.7% in H1 2026 (78.1% in H1 2025).
- · Operating income grew 24.8% YoY to $513.2M in Q2 2026 and 22.9% to $990.8M in H1 2026.
- · Diluted EPS from continuing operations was $0.42 in Q2 2026 vs $0.57 in Q2 2025, a decline of 26.3%.
- · Cash flow from operations increased 21.9% to $695.7M in H1 2026 from $570.6M in H1 2025.
- · Goodwill increased to $1,951.2M from $1,768.6M, reflecting business combinations.
- · The company recorded a $85.1M gain on remeasurement of previously held interest upon business combinations in H1 2026.
- · Total stockholders' equity increased to $10,724.9M from $10,337.6M, partly due to a new noncontrolling interest of $106.9M.
- · The effective tax rate for H1 2026 was 36.4% vs 16.1% in H1 2025, a significant increase.
04-08-2026
EVP,Chief Med Offr,Head of Dev Massacesi Cristian had withheld for taxes 26,175 Common Stock, $0.10 par value at $65.31 (~$1.71M). Massacesi Cristian holds 24,997 shares after the transaction.
- · EVP,Chief Med Offr,Head of Dev Massacesi Cristian exercised/converted 51,172 Common Stock, $0.10 par value
- · EVP,Chief Med Offr,Head of Dev Massacesi Cristian had withheld for taxes 26,175 Common Stock, $0.10 par value at $65.31 (~$1.71M)
- · EVP,Chief Med Offr,Head of Dev Massacesi Cristian exercised/converted 51,172 Restricted Stock Units
04-08-2026
Director Stevens Raymond C was awarded 181.549 Phantom shares at $194.98 (~$35.4K).
- · Director Stevens Raymond C was awarded 181.549 Phantom shares at $194.98 (~$35.4K)
04-08-2026
Director Smith Paul John was awarded 544 Humana Common. Smith Paul John holds 544 shares after the transaction.
- · Director Smith Paul John was awarded 544 Humana Common
04-08-2026
Director Zerhouni Elias A. was awarded 236.633 Phantom shares at $194.98 (~$46.1K).
- · Director Zerhouni Elias A. was awarded 236.633 Phantom shares at $194.98 (~$46.1K)
04-08-2026
Director SPOON ALAN G was awarded 229.896 Phantom shares at $194.98 (~$44.8K).
- · Director SPOON ALAN G was awarded 229.896 Phantom shares at $194.98 (~$44.8K)
04-08-2026
Director FILLER LINDA was awarded 18.333 Phantom shares at $194.98 (~$3.57K).
- · Director FILLER LINDA was awarded 18.333 Phantom shares at $194.98 (~$3.57K)
04-08-2026
Director List Teri was awarded 15.716 Phantom shares at $194.98 (~$3.06K).
- · Director List Teri was awarded 15.716 Phantom shares at $194.98 (~$3.06K)
04-08-2026
Director Sanders A Shane was awarded 211.205 Phantom shares at $194.98 (~$41.2K).
- · Director Sanders A Shane was awarded 211.205 Phantom shares at $194.98 (~$41.2K)
04-08-2026
Director Dewan Feroz was awarded 171.195 Phantom shares at $194.98 (~$33.4K).
- · Director Dewan Feroz was awarded 171.195 Phantom shares at $194.98 (~$33.4K)
04-08-2026
Baxter International Inc. announced that Anita Zielinski, Interim CFO and Senior Vice President, Chief Accounting Officer and Controller, will resign effective September 15, 2026, to join another company. Her resignation is not due to any disagreement with management or the board. The company has not yet announced a successor.
- · Resignation effective September 15, 2026.
- · No successor has been announced as of the filing date.
- · Resignation is not due to any disagreement with management or the board.
04-08-2026
Chairman & CEO O'Day Daniel Patrick sold 7,700 Common Stock at $130.80 (~$1.01M). O'Day Daniel Patrick holds 592,133 shares after the transaction. Trades executed under a Rule 10b5-1 plan.
- · Chairman & CEO O'Day Daniel Patrick sold 6,700 Common Stock at $129.66 (~$869K)
- · Chairman & CEO O'Day Daniel Patrick sold 7,700 Common Stock at $130.80 (~$1.01M)
- · Chairman & CEO O'Day Daniel Patrick sold 600 Common Stock at $131.34 (~$78.8K)
04-08-2026
See Remarks King Debra had withheld for taxes 533 Common Stock at $325.70 (~$174K). King Debra holds 7,036 shares after the transaction.
- · See Remarks King Debra had withheld for taxes 533 Common Stock at $325.70 (~$174K)
04-08-2026
VP, Chief HR Officer Fink M Kathryn had withheld for taxes 111 Common Stock at $325.70 (~$36.2K). Fink M Kathryn holds 13,027 shares after the transaction.
- · VP, Chief HR Officer Fink M Kathryn had withheld for taxes 111 Common Stock at $325.70 (~$36.2K)
04-08-2026
VP, Chief Legal Officer Fletcher Robert S had withheld for taxes 94 Common Stock at $325.70 (~$30.6K). Fletcher Robert S holds 10,488 shares after the transaction.
- · VP, Chief Legal Officer Fletcher Robert S had withheld for taxes 94 Common Stock at $325.70 (~$30.6K)
04-08-2026
VP, Chief Comm. Officer Montagnino Kimberly Ann had withheld for taxes 155 Common Stock at $325.70 (~$50.5K). Montagnino Kimberly Ann holds 1,717 shares after the transaction.
- · VP, Chief Comm. Officer Montagnino Kimberly Ann had withheld for taxes 155 Common Stock at $325.70 (~$50.5K)
04-08-2026
EVP & President, Neuroscience Thompson Kweli had withheld for taxes 1,739 Ordinary Shares at $85.39 (~$148K). 4 transactions reported in total. Thompson Kweli holds 35,390 shares after the transaction.
- · EVP & President, Neuroscience Thompson Kweli had withheld for taxes 1,739 Ordinary Shares at $85.39 (~$148K)
- · EVP & President, Neuroscience Thompson Kweli was awarded 6,923 Ordinary Shares
- · EVP & President, Neuroscience Thompson Kweli was awarded 17,306 Performance Share Units
- · EVP & President, Neuroscience Thompson Kweli was awarded 49,167 Stock Option (Right to Buy)
04-08-2026
EVP, GC and Secretary Quinn Michelle was awarded 6,346 Ordinary Shares. Quinn Michelle holds 26,721 shares after the transaction.
- · EVP, GC and Secretary Quinn Michelle was awarded 6,346 Ordinary Shares
- · EVP, GC and Secretary Quinn Michelle was awarded 15,863 Performance Share Units
- · EVP, GC and Secretary Quinn Michelle was awarded 45,070 Stock Option (Right to Buy)
04-08-2026
EVP & Chief Financial Officer Pieton Thierry was awarded 11,537 Ordinary Shares. Pieton Thierry holds 49,645 shares after the transaction.
- · EVP & Chief Financial Officer Pieton Thierry was awarded 11,537 Ordinary Shares
- · EVP & Chief Financial Officer Pieton Thierry was awarded 28,842 Performance Share Units
- · EVP & Chief Financial Officer Pieton Thierry was awarded 81,945 Stock Option (Right to Buy)
04-08-2026
EVP, Pres MedSurg and Americas Marinaro Michael had withheld for taxes 3,356 Ordinary Shares at $85.39 (~$287K). 5 transactions reported in total. Marinaro Michael holds 117,420 shares after the transaction.
- · EVP, Pres MedSurg and Americas Marinaro Michael had withheld for taxes 3,356 Ordinary Shares at $85.39 (~$287K)
- · EVP, Pres MedSurg and Americas Marinaro Michael was awarded 10,960 Ordinary Shares
- · EVP, Pres MedSurg and Americas Marinaro Michael was awarded 46,147 Ordinary Shares
- · EVP, Pres MedSurg and Americas Marinaro Michael was awarded 27,400 Performance Share Units
- · EVP, Pres MedSurg and Americas Marinaro Michael was awarded 77,848 Stock Option (Right to Buy)
04-08-2026
Chairman and CEO Martha Geoffrey had withheld for taxes 15,810 Ordinary Shares at $85.39 (~$1.35M). 5 transactions reported in total. Martha Geoffrey holds 327,866 shares after the transaction.
- · Chairman and CEO Martha Geoffrey had withheld for taxes 15,810 Ordinary Shares at $85.39 (~$1.35M)
- · Chairman and CEO Martha Geoffrey was awarded 41,533 Ordinary Shares
- · Chairman and CEO Martha Geoffrey was awarded 103,831 Performance Share Units
- · Chairman and CEO Martha Geoffrey was awarded 295,002 Stock Option (Right to Buy)
- · Chairman and CEO Martha Geoffrey was awarded 273,150 Stock Option (Right to Buy)
04-08-2026
EVP & President Cardiovascular KIIL HARRY SKIP had withheld for taxes 3,074 Ordinary Shares at $85.39 (~$262K). 4 transactions reported in total. KIIL HARRY SKIP holds 43,669 shares after the transaction.
- · EVP & President Cardiovascular KIIL HARRY SKIP had withheld for taxes 3,074 Ordinary Shares at $85.39 (~$262K)
- · EVP & President Cardiovascular KIIL HARRY SKIP was awarded 9,230 Ordinary Shares
- · EVP & President Cardiovascular KIIL HARRY SKIP was awarded 23,074 Performance Share Units
- · EVP & President Cardiovascular KIIL HARRY SKIP was awarded 65,556 Stock Option (Right to Buy)
04-08-2026
Chief Accounting Officer Blomquist Denise L. had withheld for taxes 212 Ordinary Shares at $85.39 (~$18.1K). 4 transactions reported in total. Blomquist Denise L. holds 16,998 shares after the transaction.
- · Chief Accounting Officer Blomquist Denise L. had withheld for taxes 212 Ordinary Shares at $85.39 (~$18.1K)
- · Chief Accounting Officer Blomquist Denise L. was awarded 2,337 Ordinary Shares
- · Chief Accounting Officer Blomquist Denise L. was awarded 2,337 Performance Share Units
- · Chief Accounting Officer Blomquist Denise L. was awarded 1,366 Stock Option (Right to Buy)
04-08-2026
SVP, Chief HR Officer Walter Matthew R. had withheld for taxes 1,675 Ordinary Shares at $85.39 (~$143K). 4 transactions reported in total. Walter Matthew R. holds 39,928 shares after the transaction.
- · SVP, Chief HR Officer Walter Matthew R. had withheld for taxes 1,675 Ordinary Shares at $85.39 (~$143K)
- · SVP, Chief HR Officer Walter Matthew R. was awarded 5,769 Ordinary Shares
- · SVP, Chief HR Officer Walter Matthew R. was awarded 14,421 Performance Share Units
- · SVP, Chief HR Officer Walter Matthew R. was awarded 40,973 Stock Option (Right to Buy)
Get daily alerts with 11 investment signals, 10 risk alerts, 10 opportunities and full AI analysis of all 36 filings
$30/mo after a 14-day free trial — no credit card required. See pricing or explore intelligence streams.
More from: S&P 500 Healthcare Sector SEC Filings
🇺🇸 More from United States
View all →August 04, 2026
US Pre-Market SEC Filings Roundup — August 04, 2026
US Pre-Market SEC Filings Roundup
August 04, 2026
US Earnings Financial Results SEC Filings — August 04, 2026
US Earnings Financial Results SEC Filings
August 04, 2026
S&P 500 Energy Sector SEC Filings — August 04, 2026
S&P 500 Energy Sector SEC Filings
August 04, 2026
US Merger & Acquisition SEC Filings — August 04, 2026
US Merger & Acquisition SEC Filings